Related Experiment Video
Updated: Apr 25, 2026

Author Spotlight: A Non-Intubated Video-Assisted Thoracoscopic Surgery with Multimodal Analgesia and Sevoflurane Inhalation Anesthesia
Published on: May 26, 2023
Improved outcomes associated with a revised quality measure for continuing perioperative β-blockade
Joshua S Richman1, Kamal M F Itani2, Rhiannon J Deierhoi1
1Center for Surgical, Medical Acute Care Research and Transitions, Birmingham Veterans Affairs Medical Center, Birmingham, Alabama2Section of Gastrointestinal Surgery, Department of Surgery, University of Alabama at Birmingham.
The revised Surgical Care Improvement Project perioperative beta-blocker (BB) measure improved patient outcomes, reducing major adverse cardiovascular or cerebrovascular events (MACCEs) and mortality. Adherence to the original measure, however, was linked to increased cerebrovascular events.
Area of Science:
- Cardiovascular Surgery
- Quality Improvement Initiatives
- Pharmacological Interventions
Background:
- The Surgical Care Improvement Project perioperative beta-blocker (SCIP-BB) measure was updated in 2012 to include inpatient beta-blocker continuation post-anesthesia care unit discharge.
- Evaluating adherence to both original and revised SCIP-BB measures is crucial for understanding their impact on patient safety.
Purpose of the Study:
- To assess the association between adherence to the original and revised SCIP-BB measures and the occurrence of adverse events.
- To determine if updated guidelines for perioperative beta-blocker use improve patient outcomes.
Main Methods:
- A retrospective cohort study utilized national Veterans Affairs patient data from July 2006 to August 2009.
- Propensity score matching and bootstrapping were employed to analyze the association between SCIP-BB measure adherence and major adverse cardiovascular or cerebrovascular events (MACCEs), including cardiovascular events, cerebrovascular events, and 30-day mortality.
Main Results:
- Adherence to the original SCIP-BB measure (91.3%) was not associated with reduced MACCEs but was linked to a threefold increase in cerebrovascular events.
- Adherence to the revised SCIP-BB measure (80.4%) was associated with significant reductions in MACCEs, cardiovascular events, and 30-day mortality.
- The revised measure showed no association with increased cerebrovascular events.
Conclusions:
- The original SCIP-BB measure's adherence did not improve cardiovascular outcomes and was associated with higher cerebrovascular event rates.
- Beta-blocker continuation aligned with the revised SCIP-BB measure demonstrated improved patient outcomes, including reduced MACCEs and mortality.
- Performance measures require rigorous testing before implementation; findings for the revised SCIP-BB measure warrant post-implementation evaluation.
Related Concept Videos
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Heart Failure Drugs: β-Blockers
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Dysrhythmias VII: Nursing Management of Dysrhythmias
Antihypertensive Drugs: Types of β-Blockers
